Business
Curis Announces Three Presentations at ASH
LEXINGTON, Mass., Dec. 6, 2023 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an
About this update from Curis, Inc.
[{"type":"text","content":"LEXINGTON, Mass., Dec. 6, 2023 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule IRAK4 inhibitor, today announced that the Company along with its collaborative partners will be presenting three posters at the upcoming 65th ASH Annual Meeting and Exposition (ASH 2025) being held in San Diego, California and online from December 9th to December 12th.\n\n \n \n \n \n \n \n\n \n\"We are very excited to have 3 presentations at the 65th ASH annual meeting highlighting emavusertib's continued progress in clinical studies in leukemia and lymphoma,\" said James Dentzer, President and Chief Executive Officer of Curis.\nPresentations\nTakeAim LeukemiaAbstract Title: Preliminary Safety and Efficacy of Emavusertib (CA-4948) in Acute Myeloid Leukemia Patients with FLT3 MutationAbstract Number: 2924Program: Oral and Poster AbstractsSession: 616. Acute Myeloid Leukemias: Investigational Therapies, Excluding Transplantation and Cellular Immunotherapies: Poster IISession Date and Time: Sunday, December 10, 2023, 6:00 PM-8:00 PMTakeAim LymphomaAbstract Title: Trial in Progress: An Open-Label Expansion Trial Evaluating the Safety, PK/PD, and Clinical Activity of Emavusertib (CA-4948) + Ibrutinib in R/R Primary CNS LymphomaAbstract Number: 3143Program: Oral and Poster AbstractsSession: 627. Aggressive Lymphomas: Clinical and Epidemiological: Poster IISession Date and Time: Sunday, December 10, 2023, 6:00 PM-8:00 PMAbstract Title: Takeaim Lymphoma: An Open-Label, Dose Escalation and Expansion Trial of Emavusertib (CA-4948) in Combination with Ibrutinib in Patients with Relapsed or Refractory Hematologic MalignanciesAbstract Number: 4497Program: Oral and Poster AbstractsSession: 627. Aggressive Lymphomas: Clinical and Epidemiological: Poster IIISession Date and Time: Monday, December 11, 2023, 6:00 PM-8:00 PMAbout emavusertib (CA-4948)\nEmavusertib is an orally available, small molecule IRAK4 inhibitor. IRAK4 plays an essential role in the toll-like receptor (TLR) and interleukin-1 receptor (IL-1R) signaling pathways, which are frequently dysregulated in patients with cancer. TLRs and the IL-1R family signal through the adaptor protein MYD88, which results in the assembly and activation of IRAK4, initiating a signaling cascade that induces cytoki...